바이러스 제거 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of viral clearance Market

The global viral clearance market was valued at USD 834.1 million in 2025 and is projected to grow from USD 971.65 million in 2026 to USD 3,804.75 million by 2034, registering a CAGR of 18.60% during the forecast period (2026-2034). North America accounted for the largest 37.50% market share in 2025, supported by its advanced biopharmaceutical industry, strong biotechnology research ecosystem, and increasing number of biologics manufacturing projects.

Viral clearance studies play a critical role in ensuring the safety of biologics by detecting, removing, and inactivating viral contaminants during the manufacturing process. These studies are mandatory for products derived from biological sources, including vaccines, recombinant proteins, monoclonal antibodies, blood products, and cell & gene therapies. The rapid expansion of biologics development, increasing vaccine production, and stringent regulatory requirements are significantly boosting demand for viral clearance services across the pharmaceutical and biotechnology industries. Furthermore, growing outsourcing activities to specialized contract research organizations (CROs) are accelerating market expansion.

The COVID-19 pandemic temporarily affected manufacturing activities in 2020 due to lockdowns and supply chain disruptions. However, the market recovered strongly from 2021 onward as vaccine development accelerated, biologics production increased, and clinical research activities resumed worldwide.

Latest Market Trends

One of the major trends shaping the viral clearance market is the continuous expansion of viral safety testing facilities by leading service providers. Growing demand for biologics, biosimilars, and advanced therapies has encouraged companies to establish new laboratories and increase testing capacity across major pharmaceutical hubs.

Several companies are investing heavily in specialized biosafety laboratories capable of supporting pharmaceutical manufacturers from pre-clinical development through commercialization. Facility expansion also allows companies to offer faster turnaround times, improved regulatory compliance, and enhanced testing capabilities. Increasing investments in biosafety infrastructure across North America, Europe, and Asia Pacific are expected to remain a key trend throughout the forecast period.

Market Drivers

The increasing research and development expenditure by pharmaceutical and biotechnology companies remains one of the strongest growth drivers for the viral clearance market. Rising incidences of chronic diseases, including cancer, cardiovascular disorders, autoimmune diseases, and diabetes, have significantly increased the development of biologics and biosimilars. Since every biological product requires comprehensive viral safety evaluation before commercialization, demand for viral clearance studies continues to grow steadily.

Another important growth factor is the implementation of strict global regulatory standards for biologics manufacturing. Regulatory authorities require extensive viral safety validation before granting approvals for biological drugs, vaccines, plasma-derived products, and gene therapies. International guidelines have strengthened the importance of viral clearance testing, encouraging pharmaceutical manufacturers to invest in advanced viral removal, viral detection, and viral inactivation technologies.

Market Restraints

Despite strong growth prospects, the market faces challenges due to the high cost associated with advanced viral clearance technologies and laboratory equipment. Sophisticated analytical instruments require substantial capital investment, making viral clearance services expensive for smaller biotechnology companies.

In addition, the shortage of experienced virology professionals and specialized laboratory personnel creates operational challenges for service providers. Maintaining highly qualified scientific teams while expanding testing facilities increases operational costs, which may restrict market growth in certain regions.

Market Segmentation

Based on method, the viral removal method segment is expected to dominate the global market in 2026 owing to its high efficiency in eliminating viral contaminants and increasing investments in biologics research. Viral inactivation methods are also witnessing significant adoption due to growing approvals of plasma-derived therapies and gene therapy products. Viral detection technologies continue to gain importance for ensuring comprehensive viral safety during biologics manufacturing.

By application, the vaccines segment is expected to maintain the largest market share in 2026 due to increasing immunization programs, rising vaccine production, and growing demand for preventive healthcare solutions. Blood and blood products continue to represent a significant application area, while cellular and gene therapy products are projected to register the fastest growth as regenerative medicine advances worldwide.

Based on end-user, the pharmaceutical and biotechnology industry is anticipated to remain the leading segment throughout the forecast period. Growing biologics development pipelines and stringent regulatory requirements continue to increase demand for viral clearance studies. Contract research organizations are also witnessing strong growth as pharmaceutical companies increasingly outsource viral safety testing to improve efficiency and reduce operational costs.

Regional Outlook

North America dominated the global viral clearance market with a valuation of USD 312.7 million in 2025 and is projected to reach USD 365.44 million in 2026. The region benefits from a mature pharmaceutical industry, increasing biologics production, numerous clinical trials, and substantial investments in biotechnology research.

Europe accounted for USD 231.61 million in 2025 and is expected to reach USD 264.97 million in 2026. Strong biotechnology infrastructure, increasing R&D investments, and expansion of viral testing laboratories continue to support regional growth.

Asia Pacific generated USD 256.31 million in 2025 and is forecast to reach USD 303.71 million in 2026. Rapid growth of biopharmaceutical manufacturing, rising government funding for healthcare research, expanding CRO networks, and increasing biologics production are driving demand across China, India, Japan, and other Asian countries.

Latin America and the Middle East & Africa are expected to witness steady growth due to expanding healthcare infrastructure, increasing pharmaceutical investments, and rising adoption of biologics manufacturing technologies.

Key Companies

Leading companies operating in the viral clearance market include Merck KGaA, Charles River Laboratories, WuXi Biologics, Texcell, Vironova, Kedrion, Clean Cells, ViruSure GmbH, Sartorius AG, Syngene International Limited, and Microbiologics. These companies continue expanding laboratory infrastructure, strengthening biosafety testing capabilities, and investing in advanced viral clearance technologies to meet growing global demand.

Conclusion

The viral clearance market is expected to experience substantial growth between 2026 and 2034, supported by rising biologics production, expanding vaccine development, increasing regulatory emphasis on viral safety, and growing investments in pharmaceutical research. Continuous technological advancements, expansion of biosafety laboratories, and increasing outsourcing of viral clearance studies will further strengthen market opportunities, making viral clearance an indispensable component of modern biopharmaceutical manufacturing.

Segmentation By Method

• Viral Removal Method
  • Chromatography
  • Filtration
  • Precipitation
• Viral Inactivation Method
  • pH Modification
  • Solvent Detergent (S/D)
  • Pasteurization
  • Dry Heat
  • Others
• Viral Detection Method
  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • In vivo Assay
  • In vitro Assay
  • Others

By Application

• Blood and Blood Products
• Recombinant Proteins
• Cellular & Gene Therapy Products
• Vaccines
• Others

By End-user

• Pharmaceutical and Biotech Industry
• Academic Research Institutes
• CROs
• Others

By Geography

• North America (By Method, Application, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Method, Application, End-user, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Method, Application, End-user, and Country/Sub-region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Method, Application, End-user, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Method, Application, End-user, and Country/Sub-region)
  • South Africa
  • GCC
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Technological Advancements
• 4.2. Key Industry Trends
• 4.3. Regulatory Scenario
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Method
  • 5.1.1. Viral Removal Method
    • 5.1.1.1. Chromatography
    • 5.1.1.2. Filtration
    • 5.1.1.3. Precipitation
  • 5.1.2. Viral Inactivation Method
    • 5.1.2.1. pH Modification
    • 5.1.2.2. Solvent Detergent (S/D)
    • 5.1.2.3. Pasteurization
    • 5.1.2.4. Dry Heat
    • 5.1.2.5. Others
  • 5.1.3. Viral Detection Method
    • 5.1.3.1. Next Generation Sequencing (NGS)
    • 5.1.3.2. Polymerase Chain Reaction (PCR)
    • 5.1.3.3. In vivo Assay
    • 5.1.3.4. In vitro Assay
    • 5.1.3.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Applications
  • 5.2.1. Blood and Blood Products
  • 5.2.2. Recombinant Proteins
  • 5.2.3. Cellular & Gene Therapy Products
  • 5.2.4. Vaccines
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Pharmaceutical and Biotech Industry
  • 5.3.2. Academic Research Institutes
  • 5.3.3. CROs
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Geography
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Method
  • 6.1.1. Viral Removal Method
    • 6.1.1.1. Chromatography
    • 6.1.1.2. Filtration
    • 6.1.1.3. Precipitation
  • 6.1.2. Viral Inactivation Method
    • 6.1.2.1. pH Modification
    • 6.1.2.2. Solvent Detergent (S/D)
    • 6.1.2.3. Pasteurization
    • 6.1.2.4. Dry Heat
    • 6.1.2.5. Others
  • 6.1.3. Viral Detection Method
    • 6.1.3.1. Next Generation Sequencing (NGS)
    • 6.1.3.2. Polymerase Chain Reaction (PCR)
    • 6.1.3.3. In vivo Assay
    • 6.1.3.4. In vitro Assay
    • 6.1.3.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Applications
  • 6.2.1. Blood and Blood Products
  • 6.2.2. Recombinant Proteins
  • 6.2.3. Cellular & Gene Therapy Products
  • 6.2.4. Vaccines
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Pharmaceutical and Biotech Industry
  • 6.3.2. Academic Research Institutes
  • 6.3.3. CROs
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Method
  • 7.1.1. Viral Removal Method
    • 7.1.1.1. Chromatography
    • 7.1.1.2. Filtration
    • 7.1.1.3. Precipitation
  • 7.1.2. Viral Inactivation Method
    • 7.1.2.1. pH Modification
    • 7.1.2.2. Solvent Detergent (S/D)
    • 7.1.2.3. Pasteurization
    • 7.1.2.4. Dry Heat
    • 7.1.2.5. Others
  • 7.1.3. Viral Detection Method
    • 7.1.3.1. Next Generation Sequencing (NGS)
    • 7.1.3.2. Polymerase Chain Reaction (PCR)
    • 7.1.3.3. In vivo Assay
    • 7.1.3.4. In vitro Assay
    • 7.1.3.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Applications
  • 7.2.1. Blood and Blood Products
  • 7.2.2. Recombinant Proteins
  • 7.2.3. Cellular & Gene Therapy Products
  • 7.2.4. Vaccines
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Pharmaceutical and Biotech Industry
  • 7.3.2. Academic Research Institutes
  • 7.3.3. CROs
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Method
  • 8.1.1. Viral Removal Method
    • 8.1.1.1. Chromatography
    • 8.1.1.2. Filtration
    • 8.1.1.3. Precipitation
  • 8.1.2. Viral Inactivation Method
    • 8.1.2.1. pH Modification
    • 8.1.2.2. Solvent Detergent (S/D)
    • 8.1.2.3. Pasteurization
    • 8.1.2.4. Dry Heat
    • 8.1.2.5. Others
  • 8.1.3. Viral Detection Method
    • 8.1.3.1. Next Generation Sequencing (NGS)
    • 8.1.3.2. Polymerase Chain Reaction (PCR)
    • 8.1.3.3. In vivo Assay
    • 8.1.3.4. In vitro Assay
    • 8.1.3.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Applications
  • 8.2.1. Blood and Blood Products
  • 8.2.2. Recombinant Proteins
  • 8.2.3. Cellular & Gene Therapy Products
  • 8.2.4. Vaccines
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Pharmaceutical and Biotech Industry
  • 8.3.2. Academic Research Institutes
  • 8.3.3. CROs
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Method
  • 9.1.1. Viral Removal Method
    • 9.1.1.1. Chromatography
    • 9.1.1.2. Filtration
    • 9.1.1.3. Precipitation
  • 9.1.2. Viral Inactivation Method
    • 9.1.2.1. pH Modification
    • 9.1.2.2. Solvent Detergent (S/D)
    • 9.1.2.3. Pasteurization
    • 9.1.2.4. Dry Heat
    • 9.1.2.5. Others
  • 9.1.3. Viral Detection Method
    • 9.1.3.1. Next Generation Sequencing (NGS)
    • 9.1.3.2. Polymerase Chain Reaction (PCR)
    • 9.1.3.3. In vivo Assay
    • 9.1.3.4. In vitro Assay
    • 9.1.3.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Applications
  • 9.2.1. Blood and Blood Products
  • 9.2.2. Recombinant Proteins
  • 9.2.3. Cellular & Gene Therapy Products
  • 9.2.4. Vaccines
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Pharmaceutical and Biotech Industry
  • 9.3.2. Academic Research Institutes
  • 9.3.3. CROs
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Method
  • 10.1.1. Viral Removal Method
    • 10.1.1.1. Chromatography
    • 10.1.1.2. Filtration
    • 10.1.1.3. Precipitation
  • 10.1.2. Viral Inactivation Method
    • 10.1.2.1. pH Modification
    • 10.1.2.2. Solvent Detergent (S/D)
    • 10.1.2.3. Pasteurization
    • 10.1.2.4. Dry Heat
    • 10.1.2.5. Others
  • 10.1.3. Viral Detection Method
    • 10.1.3.1. Next Generation Sequencing (NGS)
    • 10.1.3.2. Polymerase Chain Reaction (PCR)
    • 10.1.3.3. In vivo Assay
    • 10.1.3.4. In vitro Assay
    • 10.1.3.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Applications
  • 10.2.1. Blood and Blood Products
  • 10.2.2. Recombinant Proteins
  • 10.2.3. Cellular & Gene Therapy Products
  • 10.2.4. Vaccines
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Pharmaceutical and Biotech Industry
  • 10.3.2. Academic Research Institutes
  • 10.3.3. CROs
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Merck KGaA
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Wuxi Biologics
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Charles River Laboratories
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Texcell
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Vironova
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Kedrion
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Clean Cells
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. ViruSure GmbH
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Sartorius AG
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Syngene International Limited
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Microbiologics
    • 11.2.11.1. Overview
    • 11.2.11.2. Products & Services
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)